10.1177/10738584211024907 118 DrzewieckiC
da Silva RYP, de Menezes DLB, Oliveira V, da S, Converti A, de Lima AN
Is batch documentation available
As GLP-1 and GLP-2 have become important targets in the treatment of type 2 diabetes, obesity and malabsorptive conditions 16,17,62 , we therefore characterized gut microbiome signatures in DIO mice treated with liraglutide, a selective GLP-1 receptor agonist, or GUB09-145, a potent dual GLP-1/GLP-2 agonist 26
Initially, only patients with four weight-related health problems and a BMI of 40 or more (adjusted for ethnicity) will be eligible to access tirzepatide (Mounjaro) through primary care settings in England 41
Telomeres shorten with every cell division